Avadel Pharmaceuticals PLC- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Avadel Pharmaceuticals PLC 公司

Avadel Pharmaceuticals PLC 是一家生物制药公司。该公司的产品 LUMRYZ 是一种缓释型羟基丁酸钠，适用于睡前服用一次，用于治疗成人发作性睡病患者的猝倒症或白天过度嗜睡 (EDS)。该公司的方法包括将解决方案应用于药物开发，以解决患者面临的治疗选择问题。该公司的药物输送技术包括 MICROPUMP、LIQUITIME 和 MEDUSA。其 MICROPUMP 技术可用于开发缓释型固体口服剂型药物。其 LIQUITIME 技术可用于开发液体悬浮液剂型的缓释型口服产品，这可能使此类剂型特别适合儿童和/或吞咽药片或胶囊有困难的患者。其 MEDUSA 技术可用于开发缓释型注射剂型药物。

Avadel Pharmaceuticals PLC简介



公司代码AVDL

公司名称Avadel Pharmaceuticals PLC

上市日期Jan 16, 1952

CEOMr. Gregory J. (Greg) Divis, Jr.

员工数量188

证券类型Ordinary Share

年结日Jan 16

公司地址Block 10-1 Blanchardstown Corporate Park

城市DUBLIN

上市交易所NASDAQ Global Market Consolidated

国家Ireland

邮编15

电话35319015201

网址https://www.avadel.com/

公司代码AVDL

上市日期Jan 16, 1952

CEOMr. Gregory J. (Greg) Divis, Jr.

Avadel Pharmaceuticals PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

+5.27%

Mr. Peter J. Thornton

Independent Director

115.06K

+10.57%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

+14.10%

Mr. Thomas S. Mchugh

Chief Financial Officer

87.80K

-12.55%

Ms. Linda S. Palczuk

Independent Director

78.90K

+16.20%

Ms. Susan Rodriguez

Chief Operating Officer

--

Mr. Jerad Seurer

General Counsel and Corporate Secretary

--

Mr. Gregory J. (Greg) Divis, Jr.

Chief Executive Officer, Director

--

Dr. Naseem Amin, M.D.

Independent Director

--

Ms. Courtney Turiano

Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

+5.27%

Mr. Peter J. Thornton

Independent Director

115.06K

+10.57%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

+14.10%

Mr. Thomas S. Mchugh

Chief Financial Officer

87.80K

-12.55%

Ms. Linda S. Palczuk

Independent Director

78.90K

+16.20%

Ms. Susan Rodriguez

Chief Operating Officer

--

收入明细

单位: USD更新时间: 3月3日周一

FY2020

FY2019

业务USD

名称

营收

占比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

地区USD

名称

营收

占比

United States

22.33M

100.00%

Ireland

0.00

0.00%

业务

地区

业务USD

名称

营收

占比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

股东统计

更新时间: 11月11日周二

持股股东

股东类型

持股股东

占比

Janus Henderson Investors

11.40%

Brandes Investment Partners, L.P.

6.64%

Two Seas Capital LP

6.30%

BlackRock Institutional Trust Company, N.A.

6.12%

The Vanguard Group, Inc.

5.66%

其他

63.88%

持股股东

占比

Janus Henderson Investors

11.40%

Brandes Investment Partners, L.P.

6.64%

Two Seas Capital LP

6.30%

BlackRock Institutional Trust Company, N.A.

6.12%

The Vanguard Group, Inc.

5.66%

其他

63.88%

股东类型

持股股东

占比

Investment Advisor

31.44%

Investment Advisor/Hedge Fund

29.01%

Hedge Fund

24.24%

Individual Investor

4.79%

Venture Capital

3.44%

Research Firm

1.32%

Pension Fund

0.51%

Bank and Trust

0.36%

Insurance Company

0.03%

其他

4.85%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

382

84.18M

86.25%

-22.86M

2025Q2

375

87.44M

90.23%

-20.44M

2025Q1

377

85.31M

88.05%

-24.78M

2024Q4

354

86.56M

89.59%

-16.46M

2024Q3

334

81.87M

84.98%

-15.41M

2024Q2

299

81.11M

84.30%

-2.77M

2024Q1

258

76.98M

80.25%

+5.42M

2023Q4

226

62.92M

70.15%

-3.93M

2023Q3

220

60.11M

69.62%

-5.86M

2023Q2

213

57.67M

66.98%

-1.24M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Janus Henderson Investors

11.13M

11.46%

-2.46M

-18.10%

Jun 30, 2025

Brandes Investment Partners, L.P.

6.49M

6.68%

+820.47K

+14.48%

Jun 30, 2025

Two Seas Capital LP

6.16M

6.34%

+1.21M

+24.43%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.98M

6.16%

+1.29M

+27.56%

Jun 30, 2025

The Vanguard Group, Inc.

5.54M

5.71%

+1.66M

+42.73%

Jun 30, 2025

Tontine Asset Management, LLC

5.18M

5.33%

-950.54K

-15.51%

Jun 30, 2025

Polar Capital LLP

4.00M

4.12%

-356.63K

-8.19%

Jun 30, 2025

Kotler (Kevin)

3.72M

3.83%

-1.01M

-21.37%

Feb 12, 2024

Vivo Capital, LLC

2.68M

2.76%

--

Jun 30, 2025

Wealth Effects LLC

2.35M

2.43%

-14.30K

-0.60%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Invesco Pharmaceuticals ETF

2.75%

Innovator IBD 50 Fund ETF

2.64%

iShares Neuroscience and Healthcare ETF

2.45%

SPDR S&P Pharmaceuticals ETF

1.82%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.37%

iShares U.S. Pharmaceuticals ETF

0.55%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.36%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.19%

JPMorgan Fundamental Data Science Small Core ETF

0.16%

Invesco Nasdaq Biotechnology ETF

0.15%

Invesco Pharmaceuticals ETF

占比2.75%

Innovator IBD 50 Fund ETF

占比2.64%

iShares Neuroscience and Healthcare ETF

占比2.45%

SPDR S&P Pharmaceuticals ETF

占比1.82%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.37%

iShares U.S. Pharmaceuticals ETF

占比0.55%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比0.36%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.19%

JPMorgan Fundamental Data Science Small Core ETF

占比0.16%

Invesco Nasdaq Biotechnology ETF

占比0.15%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据